Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

Smoke Reader

To: duwhee who wrote (48028)	12/10/2018 6:45:41 PM
From: allatwwk	1 Recommendation Read Replies (1) of 63285

We've known for some time the risks in AA are in the more opaque area of the business, not the data around efficacy/safety. Not that this is linked, but on Aug 13, IMMU was $21.00 per share. By Aug 27, it got close to $27 and dropped back in a hurry. I'd guess it'd take a week or two for the inspection feedback to come back, well before any formal letter. I wonder if the results of this inspection, as they became known, somehow got into the market with the sense the AA filing (or timelines) might be at risk. The list of issues strikes me as correctable -- with potential for a delay in AA as opposed to a denial, but devil is often in the details here, so consider me nervous. I'd expect IMMU, with so much riding on this, is moving heaven and earth to get the issues resolved.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next